EMA
approval
· 2025-06-24
EMA Authorised: Miglustat Gen.Orph (miglustat) — Gen.Orph
Summary
The EMA authorised Miglustat Gen.Orph for the treatment of Gaucher disease, marking a new regulatory approval for this product in the EU.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Gaucher Disease. MAH: Gen.Orph. Decision date: 24/06/2025